BridgeMD
New treatment option for Abortion in First Trimester
Official title The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy
ClinicalTrials.gov ID: NCT05341817
What this study is testing
What is Letrozole?
Letrozole is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for abortion in first trimester.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Medical termination of pregnancy (mTOP) generally involves using either a combined regimen consisting of mifepristone and misoprostol, or a misoprostol-only regimen. Complete abortion rates of first trimester mTOP with the use of misoprostol-only regimen varies between 74-88%.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 and older, women only
You may be able to join if
- 21 years and above
- Patient requesting for medical termination of pregnancy (mTOP)
- Patient eligible for legal abortion according to the Termination of Pregnancy Act (Chapter 324)
- Gestational age ≤10 weeks (on day 1 of mifepristone or letrozole administration) as confirmed by the first trimester dating scan
- Singleton pregnancy
You likely can't join if
- History or evidence of adrenal pathology, steroid-dependent cancer, porphyria, poorly controlled hypertension, bronchial asthma, thromboembolism and...
- Haemoglobin level of \<9.5 g/L
- Presence of an intrauterine contraceptive device
- Breastfeeding
- Reported allergic reaction to mifepristone, misoprostol or letrozole,
- Participating in another trial of investigational medicinal products during the current pregnancy
See the full eligibility criteria
- 21 years and above
- Patient requesting for medical termination of pregnancy (mTOP)
- Patient eligible for legal abortion according to the Termination of Pregnancy Act (Chapter 324)
- Gestational age ≤10 weeks (on day 1 of mifepristone or letrozole administration) as confirmed by the first trimester dating scan
- Singleton pregnancy
- Patient is agreeable to undergo surgical evacuation or repeat medical therapy if treatment fails
- Willing and able to provide written, informed consent
- History or evidence of adrenal pathology, steroid-dependent cancer, porphyria, poorly controlled hypertension, bronchial asthma, thromboembolism and severe cardiac/renal/liver disease
- Haemoglobin level of \<9.5 g/L
- Presence of an intrauterine contraceptive device
- Breastfeeding
- Reported allergic reaction to mifepristone, misoprostol or letrozole,
- Participating in another trial of investigational medicinal products during the current pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Singapore, Singapore
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 21 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore, Singapore. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.